MA30921B1 - Formes cristallines de l'aliskiren (hemifumarate) - Google Patents

Formes cristallines de l'aliskiren (hemifumarate)

Info

Publication number
MA30921B1
MA30921B1 MA31922A MA31922A MA30921B1 MA 30921 B1 MA30921 B1 MA 30921B1 MA 31922 A MA31922 A MA 31922A MA 31922 A MA31922 A MA 31922A MA 30921 B1 MA30921 B1 MA 30921B1
Authority
MA
Morocco
Prior art keywords
crystalline forms
hemifumarate
aliskiren
pharmaceutical preparations
pharmaceutical
Prior art date
Application number
MA31922A
Other languages
English (en)
Inventor
Frank Stowasser
Stephanie Monnier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37907983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30921(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30921B1 publication Critical patent/MA30921B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

CETTE INVENTION CONCERNE LES FORMES CRISTALLINES DE L'ALISKIREN (HÉMIFUMARATE) ET DIVERS MODES DE RÉALISATION QUI SONT ASSOCIÉS, PAR EXEMPLE LES PRÉPARATIONS PHARMACEUTIQUES, LES PROCESSUS DE FABRICATION DES FORMES CRISTALLINES, LES UTILISATIONS PHARMACEUTIQUES, ETC. LES FORMES CRISTALLINES ONT DES PROPRIÉTÉS PARTICULIÈREMENT AVANTAGEUSES, ELLES SONT NOTAMMENT UTILES DANS LA FABRICATION DES PRÉPARATIONS PHARMACEUTIQUES DESTINÉES À RÉDUIRE LA PRESSION ARTÉRIELLE.
MA31922A 2006-11-07 2009-05-27 Formes cristallines de l'aliskiren (hemifumarate) MA30921B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06123642 2006-11-07

Publications (1)

Publication Number Publication Date
MA30921B1 true MA30921B1 (fr) 2009-11-02

Family

ID=37907983

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31922A MA30921B1 (fr) 2006-11-07 2009-05-27 Formes cristallines de l'aliskiren (hemifumarate)

Country Status (25)

Country Link
US (1) US8119841B2 (fr)
EP (1) EP2079463A1 (fr)
JP (1) JP2010508370A (fr)
KR (1) KR20090083918A (fr)
CN (1) CN101594857B (fr)
AR (1) AR063560A1 (fr)
AU (1) AU2007323465B2 (fr)
BR (1) BRPI0718546A2 (fr)
CA (1) CA2668828A1 (fr)
CL (1) CL2007003194A1 (fr)
CO (1) CO6180428A2 (fr)
EC (1) ECSP099385A (fr)
GT (1) GT200900116A (fr)
IL (1) IL198470A0 (fr)
MA (1) MA30921B1 (fr)
MX (1) MX2009004885A (fr)
MY (1) MY148758A (fr)
NO (1) NO20092102L (fr)
NZ (1) NZ577320A (fr)
PE (2) PE20121179A1 (fr)
RU (1) RU2466982C2 (fr)
TN (1) TN2009000174A1 (fr)
TW (1) TW200827326A (fr)
WO (1) WO2008061622A1 (fr)
ZA (1) ZA200902941B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120029083A1 (en) * 2007-11-13 2012-02-02 Teva Pharmaceutical Industries, Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
CA2712087A1 (fr) 2008-01-23 2009-07-30 Novartis Ag Procede d'optimisation du traitement de maladies proliferatives a mediation par recepteur a tyrosine kinase kit avec de l'imatinib
EP2143425A1 (fr) * 2008-07-11 2010-01-13 Ratiopharm GmbH Tablettes d'aliskiren comprimées directement
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
KR20170062554A (ko) * 2008-12-18 2017-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
EP2393489B1 (fr) 2009-02-05 2014-10-08 Krka, tovarna zdravil, d.d., Novo mesto Processus de granulation à humidité activée
US8148576B2 (en) * 2009-02-05 2012-04-03 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
WO2011028919A2 (fr) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Formes solides d'hémifumarate d'aliskirène et leurs procédés de préparation
CN102617392B (zh) * 2011-01-28 2015-04-01 博瑞生物医药技术(苏州)有限公司 一种阿利克仑半富马酸盐晶型ⅰ的制备方法
ITMI20111291A1 (it) * 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato etil acetato solvato
ITMI20111290A1 (it) * 2011-07-11 2013-01-12 Djada Pharmaceutical Sa Aliskiren emifumarato, forma cristallina e solido amorfo
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
JP6007096B2 (ja) * 2011-12-28 2016-10-12 エルメッド エーザイ株式会社 安定化カンデサルタンシレキセチル含有物の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
BR0112362B1 (pt) * 2000-07-05 2013-12-31 Processo para a preparação de octanoil amidas substituídas e compostos intermediários
RU2316318C2 (ru) * 2002-05-17 2008-02-10 Новартис Аг Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2007323465A1 (en) 2008-05-29
MX2009004885A (es) 2009-05-19
RU2009121651A (ru) 2010-12-20
PE20121179A1 (es) 2012-09-13
CO6180428A2 (es) 2010-07-19
ECSP099385A (es) 2009-07-31
CN101594857A (zh) 2009-12-02
NO20092102L (no) 2009-07-30
JP2010508370A (ja) 2010-03-18
CA2668828A1 (fr) 2008-05-29
CL2007003194A1 (es) 2008-06-13
US8119841B2 (en) 2012-02-21
AU2007323465B2 (en) 2011-08-04
PE20081157A1 (es) 2008-09-26
MY148758A (en) 2013-05-31
WO2008061622A1 (fr) 2008-05-29
TN2009000174A1 (en) 2010-10-18
GT200900116A (es) 2011-06-07
AR063560A1 (es) 2009-02-04
TW200827326A (en) 2008-07-01
EP2079463A1 (fr) 2009-07-22
CN101594857B (zh) 2012-10-31
US20100048716A1 (en) 2010-02-25
NZ577320A (en) 2012-01-12
ZA200902941B (en) 2010-03-31
RU2466982C2 (ru) 2012-11-20
KR20090083918A (ko) 2009-08-04
IL198470A0 (en) 2010-02-17
BRPI0718546A2 (pt) 2013-11-19

Similar Documents

Publication Publication Date Title
MA30921B1 (fr) Formes cristallines de l'aliskiren (hemifumarate)
MA31822B1 (fr) Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues
BR0213358A (pt) Uso de flibanserina
BRPI0410767A (pt) formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores
MA28182A1 (fr) Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues
DOP2002000429A (es) Imidazotriazinas
PH12014501960A1 (en) Modified factor vii polypetides and uses thereof
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
AR054139A1 (es) Formulacion modificada y de liberacion inmediata de esferas de memantina
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BRPI0609711B8 (pt) uso de uma solução aquosa com potencial redutivo oxidativo (orp)
WO2005102392A3 (fr) Methodes de traitement d'une infection a vih
UA91729C2 (ru) Твердая форма лекарственного препарата
BRPI0407181A (pt) Formulação farmacêutica
DK1765337T3 (da) Kombination af tenofovir, ritonavir og TMC114
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
TNSN02015A1 (fr) Composes nouveaux antagonistes de ppar, et compositions les contenant
MA31264B1 (fr) Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison
ATE366106T1 (de) Zusammensetzung für die pharmazeutische oder dietätische verwendung zur bekämpfung von haarausfall
NI200700175A (es) Procesos para la preparación de alcoholes de aminoetoxibencilo
PT1368016E (pt) Formas de dosagem parenterica que compreendem uma suspensao de sal de tramadol e sal de diclofenac
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
NO20051301L (no) Proteintyrosinforfataseinhibitorer
BR9707083A (pt) Formas sólidas de administração com liberação instantánea e processos para a sua produção